We note that in the CAMELIA trial, the CFR was substantially higher than our estimate (18% and 27% for those initiating ART two or eight weeks into TB treatment), but this is likely to be due to the very low baseline CD4 count of patients included in that study (median  = 25 cells/mm3) and the longer follow-up time (median  = 25 months) [6]. The gene discussed is CD4; the disease is tuberculosis.